Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
MetaVia ( (MTVA) ) just unveiled an announcement.
On July 9, 2025, MetaVia Inc. announced the dosing of the first patient in the 48 mg cohort of its Phase 1 clinical trial for DA-1726, a novel dual oxyntomodulin analog agonist for obesity treatment. The trial aims to explore the maximum tolerated dose, with top-line data expected in the fourth quarter of 2025. Previous data from a 32 mg dose showed promising results in weight loss, glucose control, and waist reduction, suggesting DA-1726’s potential as a superior alternative to current GLP-1 therapies. The Phase 1 trial is a randomized, double-blind, placebo-controlled study focusing on safety, tolerability, and pharmacokinetics in obese subjects.
The most recent analyst rating on (MTVA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
Spark’s Take on MTVA Stock
According to Spark, TipRanks’ AI Analyst, MTVA is a Underperform.
MetaVia’s overall stock score is heavily impacted by its poor financial performance, characterized by persistent losses and no revenue generation. The technical analysis indicates weak market momentum, and negative valuation metrics highlight the stock’s high-risk profile. Although recent positive trial results provide some potential for future growth, significant strategic changes are necessary for the company to achieve financial stability and investor confidence.
To see Spark’s full report on MTVA stock, click here.
More about MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is developing DA-1726 for obesity treatment and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin analogue functioning as a dual agonist of GLP1R and GCGR, potentially offering superior weight loss compared to selective GLP1R agonists.
Average Trading Volume: 737,125
Technical Sentiment Signal: Sell
Current Market Cap: $12.19M
For a thorough assessment of MTVA stock, go to TipRanks’ Stock Analysis page.